Skip to content
value.today

Omthera Pharmaceuticals, Inc.

🇺🇸 Gladstone, New Jersey, USAPharmaceuticalsFounded 2008
Total raised
$59 M
3 rounds on record
Latest round
$18 M
Feb 2013
First round on record
Nov 2009
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Omthera Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2013$18 MNo. 3$10 to $50 million

Omthera Pharmaceuticals, Inc.: Raise no. 3, Feb 2013

Investors in this round

13 investors had bought by the notice of Feb 28, 2013: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Omthera Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$18 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bernardus Machielse · Executive Officer
  • Christian Schade · Executive Officer
  • Gerald Wisler · Executive Officer, Director
  • Michael Davidson · Executive Officer
  • David Mott · Director
  • George Horner · Director
  • Graziano Seghezzi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gerald Wisler, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 28, 2013. Read the notice at the SEC.

debt, optionsSEC
Feb 2011$39 MNo. 2$10 to $50 million

Omthera Pharmaceuticals, Inc.: Raise no. 2, Feb 2011

Investors in this round

10 investors had bought by the notice of Jan 6, 2012: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Omthera Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$39 M of $49 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christian Schade · Executive Officer
  • Gerald Wisler · Executive Officer, Director
  • David Mott · Director
  • George Horner · Director
  • Graziano Seghezzi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Some of the funds will be used as working capital and therefore to pay normal business expenses, such as salaries of officers.”

Signed by Christian Schade, Secretary and Treasurer. Source: SEC Form D and 1 amendment, newest notice filed Jan 6, 2012. Read the notice at the SEC.

equitySEC
Nov 2009$2 MNo. 1$2 to $10 million

Omthera Pharmaceuticals, Inc.: Raise no. 1, Nov 2009

Investors in this round

4 investors had bought by the notice of Nov 27, 2009: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Omthera Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$400,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Douglas Carr · Executive Officer
  • Gerald Wisler · Executive Officer, Director
  • Graziano Seghezzi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds will be used for operating expenses, including salaries.”

Signed by Gerald Wisler, President. Source: SEC Form D, newest notice filed Nov 27, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Omthera Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2013).

    SEC Form D · Feb 2013

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Feb 2013

That is all the official record says: Omthera Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

9 named in official filings. Open an investor to see everything it has backed.

Investors in Omthera Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
Bernardus N. M. MachielsePersonnot statednot statedHeld Series B preferred stock (Form 3, 2013)SEC Form 3
Christian S. SchadePersonnot statednot statedHeld Series B preferred stock (Form 3, 2013)SEC Form 3
Gerald WislerPersonnot statednot statedHeld Series B preferred stock, director (Form 3, 2013)SEC Form 3
Michael H. DavidsonPersonnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2013)SEC Form 3
NEA 13 GP, LtdCompanynot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2013)SEC Form 3
NEA Partners 13, Limited PartnershipFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2013)SEC Form 3
New Enterprise Associates 13 LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Sofinnova Capital VI FcprFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Sofinnova Partners SASFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2013)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 13 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Omthera Pharmaceuticals, Inc.
NameRoleNamed in
Bernardus MachielseExecutive officerFeb 2013
Christian SchadeExecutive officerFeb 2013
Gerald WislerExecutive officerFeb 2013
Michael DavidsonExecutive officerFeb 2013
Douglas CarrExecutive officerMar 2011
David MottDirectorFeb 2013
George HornerDirectorFeb 2013
Gerald WislerDirectorFeb 2013
Graziano SeghezziDirectorFeb 2013